GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LCI699

Company
Novartis
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for LCI699 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT03708900

    Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

    Not yet reported RECORDATI GROUP 12 participants Est. completion 2027-07-21 15 sites Stand-alone
    Other conditions: Cushing Syndrome
    View official trial listing →
  • Recruiting NCT NCT07247058

    Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

    Not yet reported Johns Hopkins University 10 participants Est. completion 2029-03 1 site
    Other conditions: Mild Autonomous Cortisol Secretion (MACS)
    View official trial listing →
  • Completed NCT NCT00732771

    Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

    Not yet reported Novartis 12 participants 1 site Stand-alone
    Other conditions: Primary Hyperaldosteronism
    View official trial listing →
  • Completed NCT NCT00758524

    A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

    Not yet reported Novartis Pharmaceuticals 628 participants Est. completion 2009-07-02 1 site Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT00817414

    A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

    Not yet reported Novartis 63 participants Est. completion 2009-08-12 11 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00817635

    A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

    Not yet reported Novartis 155 participants Est. completion 2009-10-13 38 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT01331239

    Safety and Efficacy of LCI699 in Cushing's Disease Patients

    Not yet reported Novartis Pharmaceuticals 31 participants Est. completion 2019-10-22 10 sites Stand-alone
    Other conditions: Cushings Disease, Cushing Disease
    View official trial listing →
  • Completed NCT NCT02180217

    Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 137 participants Est. completion 2019-12-04 60 sites Stand-alone
    Other conditions: Cushings Disease
    View official trial listing →
  • Completed NCT NCT02372084

    A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

    Not yet reported Novartis Pharmaceuticals 33 participants Est. completion 2016-05-19 3 sites Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
  • Completed NCT NCT02399202

    A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

    Not yet reported Novartis Pharmaceuticals 15 participants Est. completion 2016-03-21 2 sites Stand-alone
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT02468193

    Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2018-10-29 4 sites
    Other conditions: Cushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma, Adrenal Carcinoma, AIMAH, PPNAD
    View official trial listing →
  • Completed NCT NCT02697734

    Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

    Not yet reported Novartis Pharmaceuticals 73 participants Est. completion 2020-12-31 36 sites
    Other conditions: Cushing's Disease
    View official trial listing →
  • Completed NCT NCT03606408

    Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

    Not yet reported RECORDATI GROUP 127 participants Est. completion 2023-11-16 56 sites
    Other conditions: Cushing's Syndrome
    View official trial listing →
  • Status unknown NCT NCT06131580

    Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome

    Not yet reported Centre hospitalier de l'Université de Montréal (CHUM) 7 participants Est. completion 2025-11-24 3 sites
    Other conditions: Endogenous Cushing Syndrome
    View official trial listing →
  • Not yet recruiting NCT NCT07247162

    Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

    Not yet reported RECORDATI GROUP 63 participants Est. completion 2028-07 Stand-alone
    Other conditions: Hypertension, Hypercortisolemia, Cushing Syndrome
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.